Bristol Myers Squibb has struck a deal with Anthropic to roll out Claude across the entire company. The rollout covers R&D, manufacturing, clinical development and commercial, all of it, and reaches more than 30,000 employees.
The point isn’t another chatbot. BMS is building AI directly into the day-to-day workflows that actually move drugs through the pipeline. A $120B pharma giant has gone this far, and the rest of the industry is certainly taking notes. The enterprise AI era in drug development has arrived.